Best Marijuana Stocks to keep focused on, This is our Focus List
*Note* We are currently hard at work to populate this page with the best marijuana stocks and information possible. It is important to state that although we do offer advertising on this website, NO company and or “3rd party” can pay to have their company listed on our focus list. However we do reserve the right to publish a company that has advertised and or plans to advertise on this website and we will responsibly disclaim such compensation clearly for all to see. This is a list provided by Marijuana Stocks.
AbbVie Inc. (NYSE: ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Their Marinol drug is FDA-approved for the treatment of nausea in patients undergoing chemotherapy and is also prescribed to AIDS patients suffering from loss of appetite. The drug is made of a synthetic form of THC and is delivered as an oral capsule.
Although the DEA still classifies marijuana as a Schedule I drug, Marinol is listed as a Schedule III drug, meaning the FDA recognizes the clinical benefits and abuse potentials are believed to be lower.
The company also offers Humira, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; Imbruvica an oral therapy for the treatment of chronic lymphocytic leukemia; and Viekira Pak, an interferon-free therapy for adults with genotype 1 chronic hepatitis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses.
Aurora Cannabis Inc. (ACB.CN) (OTC: ACBFF)
Aurora Cannabis Inc. focuses on cultivating, harvesting, and selling medical marihuana in Canada. The company is based in Vancouver, Canada. Using water from the Canadian Rocky Mountains, Aurora cannabis plants are brought to harvest in their 55,200 sq ft. facility. Their state-of-the-art facility is designed to produce the cleanest, safest medical cannabis available on the market. Focused on providing high quality medical cannabis at affordable pricing, Aurora offers patients who register with them $8/gram strain pricing, $5/gram composite pricing, a $50 cannabis credit, free shipping Canada-wide, and influence future strains and products.
Cara Therapeutics Inc. (NASDAQ: CARA)
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company, focusing on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. Cara is developing lead molecules that selectively modulate peripheral CB receptors without targeting CNS cannabinoid receptors. Peripheral CB receptor modulators will be initially developed as a novel therapeutic approach for neuropathic and inflammatory pain, a condition currently without consistently effective therapies. Cara’s most advanced CB compound, CR701, is currently in preclinical development.
The company is also developing cannabis-based product candidates that target the body’s peripheral nervous system. Its lead product candidate includes I.V. CR845, which is in Phase III clinical trials for the treatment of acute postoperative pain in adult patients, as well as completed Phase II clinical trials for the treatment of uremic pruritus disease, an intractable systemic itching condition which occurs among people with Chronic Kidney Disease. The company is also developing Oral CR845, which is in Phase IIa clinical trials for the treatment of moderate-to-severe acute and chronic pain. It has licensing agreements with Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize products containing CR845 in South Korea; and Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan.
GW Pharmaceuticals plc (NASDAQ: GWPH)
GW Pharmaceuticals plc is a biopharmaceutical company that, together with its subsidiaries, engages in discovering, developing, and commercializing cannabinoid prescription medicines. It operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company primarily offers Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. It also focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain; and Phase 2 trials in other indications, such as neuropathic pain. In addition, the company’s product pipeline includes Epidiolex, a treatment for Dravet syndrome and Lennox-Gastaut syndrome, as well as other product candidates in Phase 1 and 2 clinical development for the treatment of glioma, adult epilepsy, type-2 diabetes, and schizophrenia. In a Phase III trial for Epidiolex, the drug reduced the frequency of seizures by 39% in children with a form of epilepsy known as Dravet syndrome, compared to a 13% reduction in children who took a placebo. It operates in the United Kingdom, Europe, the United States, Canada, and Asia.
INSYS Therapeutics Inc. (NASDAQ: INSY)
Insys Therapeutics, Inc., a specialty pharmaceutical company developing and commercializing supportive care products, has two FDA-approved cannabis-based drugs and seven more drugs in the pipeline. Their Subsys is a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is Syndros, an orally administered liquid formulation of dronabinol. Syndros helps patients with anorexia symptoms related to weight loss from AIDS. The drug, which is a pharmaceutical formulation of tetrahydrocannabinol (THC), was approved by the American regulatory agency as a therapy to stimulate patients’ hunger, as well as a treatment for the nausea and vomiting that is involved with cancer chemotherapy – which is prescribed to patients who do not respond well enough to standard antiemetic (anti-vomitin) treatments. Also in development, Cannabidiol Oral Solution is a synthetic cannabidiol for childhood catastrophic epilepsy syndromes. The company is also developing other dronabinol line extensions and sublingual spray product candidates.
MassRoots Inc (OTCMKTS: MSRT)
MassRoots is one of the largest and most active technology platforms for cannabis consumers, businesses and activists with over 900,000 registered users. It is proud to be affiliated with the leading organizations in the cannabis industry, including the ArcView Group and National Cannabis Industry Association. MassRoots has been making many strides recently with regards to increasing it’s revenue via new advertising functions for the cannabis industry as well as reducing it’s overall expenditures. As the industry expands year over year, platforms like Massroots will be providing individuals and companies avenues for advertisement as an alternative to Facebook & Google which have shunned cannabis based ads. For more information, please visit MassRoots.com/Investors.
mCig Inc. (OTC: MCIG)
mCig, Inc. manufactures, markets, and distributes electronic cigarettes, vaporizers, and accessories under the mCig and VitaCig brand name in the United States. It offers electronic cigarettes and related products through its online store mcig.org, as well as through the company’s wholesale, distributor, and retail programs. The company also provides marijuana grower services such as commercial grow room design, warehouse customization, greenhouse grows, personal home grow room units, and general marijuana business consulting.
The Scotts Miracle-Gro Company (NYSE: SMG)
The Scotts Miracle-Gro Company is most well-known for the manufacturing, marketing, and selling of their extensive line of consumer lawn and garden products worldwide. Popular brand names include Scotts, Turf Builder, EZ Seed, Water Smart, PatchMaster, EverGreen, Miracle-Gro Patch Magic, Weedol, Pathclear, EdgeGuard, OxiClean, Miracle-Gro, Earthgro, SuperSoil, Miracle-Gro Organic Choice, Nature’s Care, Whitney Farms, EcoScraps, General Hydroponics, Scotts EcoSense, Tomcat, Roundup, and Home Defence to name a few. But CEO Jim Hagedorn is making big bets in hydroponics as he believes legal marijuana is a billion dollar opportunity and the biggest thing ever to happen to the lawn and gardening industry. The company shelled out $136 million for Gavita, a Dutch grow lighting and hardware company, and inked a deal to buy Arizona-based Botanicare, a plant nutrient and hydroponics products provider that notched about $40 million in sales. The company also invested heavily in Boulder’s AeroGrow indoor gardening company. In addition, the company bought out California’s General Hydroponics last year for $130 million.
The company also has a Scotts LawnService segment that offers residential and commercial lawn care, tree and shrub care, and pest control services through the periodic applications of fertilizer and control products.
Canopy Growth Corporation (CGC.V) (OTC: TWMJF)
Canopy Growth Corporation, through its subsidiaries, produces and sells medical marijuana in Canada. They operate a collection of diverse brands and curated strain variety, supported by over half a million square feet of indoor greenhouse production capacity. The company offers dry cannabis and oil products primarily under the Tweed and Bedrocan brands. It also sells its products online. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. The company acquired Bedrocan Cannabis Corp. in 2015 for approximately $58 million. Canopy Growth is the largest producer of medical marijuana in Canada.
Vitality Biopharma, Inc. (OTC: VBIO)
Cannabosides – A New Class of Cannabinoid Pharmaceuticals
Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract.
Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation.
Independent clinical trial results suggest that cannabinoids will help induce remission in Crohn’s disease patients, and that the vast majority of inflammatory bowel disease (“IBD”) patients experience symptomatic relief, including 84% of patients who report improvement in visceral or abdominal pain. Approximately 1.4 million Americans have IBD, including Crohn’s disease and ulcerative colitis. Most patients are diagnosed before age 30 and require life-long treatment.
A prodrug is a medication or compound that, after administration, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Prodrugs are typically designed to overcome well-known drawbacks of currently available therapies. Vitality’s prodrug technology enables the selective targeting of specific tissues or organs, including the gut or brain, enabling the drug to have a more targeted effect. As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.
Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE)
Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates include ZYN002, which is in Phase I clinical trial for the treatment of refractory epilepsy, Fragile X syndrome, and osteoarthritis; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain